FAQ on Clene Inc.'s Neurofilament Biomarker Analyses for CNM-Au8 in ALS and MS

What is Clene Inc. preparing to initiate?

Clene Inc. is preparing to initiate neurofilament biomarker analyses for its lead drug candidate CNM-Au8 in ALS, following feedback from the FDA.

Why is the neurofilament light chain (NfL) biomarker analysis important?

The NfL biomarker analysis is important because it assesses changes in a recognized marker for neurodegeneration, offering insights into the drug’s potential impact on ALS patients.

How does CNM-Au8 work?

CNM-Au8 improves central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.

Who is involved in the upcoming analyses?

The analyses will involve nearly 200 patients treated through the Expanded Access Program for CNM-Au8, with Clene Inc. and the FDA collaborating on the process.

When are the neurofilament biomarker analyses slated to begin?

The analyses are slated to begin in early Q4 2025.

Where can I find more information about Clene Inc.?

More information about Clene Inc. can be found on their website at www.Clene.com.

What are the implications of this research for neurodegenerative diseases?

This research could lead to innovative therapies for neurodegenerative diseases like ALS and MS, improving patients’ quality of life and survival rates.

How can investors stay updated on Clene Inc.’s progress?

Investors can stay updated by visiting the company’s newsroom at https://ibn.fm/CLNN.